Global Livestock Vaccine Market Accelerates Toward $16 Billion

15/09/2025

The global livestock vaccine sector is entering a decisive growth phase. Analysts now expect the market to expand from USD 10.7 billion in 2024 to USD 16.1 billion by 2030, supported by a strong CAGR of around 7%. The momentum reflects growing awareness of zoonotic disease risks, consumer demand for safe and traceable animal protein, and stricter government mandates for preventive health.

Industry leaders Zoetis, Merck Animal Health, Boehringer Ingelheim, and Ceva Santé Animale remain dominant, but the dynamics are shifting. Regional players in Asia and Latin America are building capacity quickly, supported by state-backed vaccination programs that aim to reduce reliance on imports.

The economic rationale is clear. Outbreaks of diseases like foot-and-mouth, avian influenza, or bluetongue have historically triggered billions in trade restrictions, herd culling, and compensation payouts. Vaccination helps reduce the scale of such shocks, protecting farmers and stabilizing national food security. For investors, the market is attractive because it provides recurring revenue streams — livestock need regular boosters to maintain herd immunity.

But the picture is uneven. In developing markets, uptake is slowed by limited cold-chain infrastructure, high distribution costs, and shortages of antigens. This creates a two-tier market: well-served developed economies and under-protected regions where disease outbreaks remain a recurring threat. Closing that gap will define the next phase of growth.